

References

References

1. Abel, J., Rowntree, L. G., and Turner, B. B., "Plasma Removal With Return of Corpuscles," *J. Pharmacol. Exp. Ther.* 5:625-641, 1914.
2. Altman, L. K., "Bloodletting Is Revived for a Wide Variety of Modern Ills," *New York Times*, sec. C., p. 1, Apr. 27, 1982.
3. Altman, S. H., and Blendon, R. (eds.), *Medical Technology: The Culprit Behind Health Care Costs*, proceedings of the 1977 Sun Valley Forum on National Health, DHEW publication No. (PHS) 79-3216 (Washington, D. C.: Government Printing Office, August 1977).
4. American College of Physicians, Clinical Efficacy Assessment Project, "Apheresis for the Treatment of Goodpasture's Syndrome, Systemic Lupus Erythematosus, Membranous and Proliferative Glomerulonephritides, Multiple Sclerosis, Potentially Life-Threatening Complications of Rheumatic Diseases, and Thrombotic Thrombocytopenic Purpura," unpublished draft statement, Philadelphia, Pa., July 20, 1982.
5. American Medical Association, Council on Scientific and Medical Affairs, Apheresis Panel, "Minutes of the Apheresis Panel," Chicago, Ill., June 19, 1982.
6. American Society of Hematology, "On the Use of Apheresis for Treatment of Hematologic Disorders," prepared for the National Center for Health Care Technology, Office of the Assistant Secretary for Health, Department of Health and Human Services, Rockville, Md., September 1981.
7. American Society of Hematology, "Statement by the American Society of Hematology on the Use of Apheresis for Treatment of Hematologic Disorders," unpublished, Thorofare, N. J., 1981.
8. Anthony, J., Baxter Travenol Laboratories, Inc., Deerfield, Ill., personal communication, December 1982.
9. Arthritis Foundation, "Recommendations of the Arthritis Foundation and the American Rheumatism Association on Plasmapheresis in Rheumatic Diseases," unpublished, Atlanta, Ga., February 1981.
10. Asbury, A., Fisher, R., McKhann, G. M., et al., "Guillain-Barré Syndrome: Is There a Role for Plasmapheresis?" *Neurology* 30:1112, 1980.
11. Beattie, T. J., Murphy, A. V., Willoughby, M. L. N., et al., "Plasmapheresis in the Hemolytic-Uraemic Syndrome in Children," *Br. Med. J.* 282:1667-1668, 1981.
12. Berkman, E., "Issues in Therapeutic Apheresis," editorial, *N. Engl. J. Med.* 306(23):1418-1420, 1982.
13. Borberg, H., "Problems of Plasma Exchange Therapy," in *Therapeutic Plasma Exchange*, H. J. Gurland, V. Heinze, and H. A. Lee (eds.) (Berlin: Springer-Verlag, 1981).
14. Bowman, J. M., Peddle, L. J., and Anderson, C., "Plasmapheresis in Severe Rh-iso-immunization," *Vox Sang.* 15:272, 1968.
15. Brettle, R. P., Gross, M., Legg, N. J., et al., "Treatment of Acute Polyneuropathy by Plasma Exchange," letter, *Lancet* 2:1100, 1971.
16. Bucu, M., Blue Cross-Blue Shield Association, Chicago, Ill., letter to Travenol Laboratories, Inc., Deerfield, Ill., Oct. 27, 1982.
17. Bunker, J. P., Hinkle, D., and McDermott, W. v., "Surgical Innovation and Its Evaluation," *science* 200:937-941, 1978.
18. Burton, R., *Anatomy of Melancholy* (New York: Vintage Books, Random House, 1977).
19. Center for the Analysis of Health Practices, Harvard School of Public Health, "Impact on Health Costs of NCHCT Recommendations for Nonreimbursement for Medical Procedures," prepared for the National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., Apr. 15, 1981.
20. Ciarkowski, A. A., Food and Drug Administration, Department of Health and Human Services, Silver Spring, Md., personal communication, August 1982.
21. Ciarkowski, A. A., Food and Drug Administration, Department of Health and Human Services, Silver Spring, Md., personal communication, December 1982.
22. Ciuryla, V. T., E. I. du Pont de Nemours & Co., Inc., Wilmington, Del., personal communication, December 1982.
23. Cobcroft, R., Tamagnini, G., and Dornandy, K. M., "Serial Plasmapheresis in a Hemophiliac With Antibodies to Factor VIII," *J. Clin. Pathol.* 30:763-765, 1977.
24. Collins, R. M., Cobe Laboratories, Inc., Lakewood, Colo., personal communication, December 1982.
25. Cook, T. D., and Campbell, D. T., *Quasi-Experimentation: Design and Analysis of Research in Field Settings* (Chicago: Rand McNally, 1979).
26. Cook, T. D., Tindall R. A. S., Walker, J., et al., "Plasma Exchange as a Treatment of Acute and Chronic Idiopathic Autoimmune Polyneuropathy: Limited Success," *Neurology* 30:361, 1980.
27. Corachan, M., Talonu, T., Oldfield, E., et al., "Treatment of Acute Severe Guillain-Barré Syndrome by Plasmapheresis," *Papua New Guinea Med. J.* 23:146-147, 1980.

28. Cotter, D., Office of Health Technology Assessment, Department of Health and Human Services, Rockville, Md., personal communication, March 1983.
29. Cotter, D., Office of the Assistant Secretary for Health, Department of Health and Human Services, Rockville, Md., personal communication, July 1982.
30. Dau, P. C., Children's Hospital, San Francisco, Calif., 1981, as reported by Travenol Laboratories, Inc., Deerfield, Ill., personal communication, December 1982.
31. Dau, P. C., Miller, R. G., and Denys, E. H., "Experience With Plasmapheresis in 153 Neurologic Patients," *Int. J. Artif. Org.* 5(1):37-46, 1982.
32. Douma, A. J., American Medical Association, Chicago, Ill., personal communication, August 1982.
33. Durward, W. F., Burnett, A. K., Watkins, R., et al., "Plasma Exchange in Guillain-Barré Syndrome," *Br. Med. J.* 283:794, 1981.
34. Edelson, E., "Cleansing the Blood," *Science* 82 (American Association for the Advancement of Science, Washington, D.C.), 3(8):72-77, October 1982.
35. Edmondson, F. W., Travenol Laboratories, Inc., Deerfield, Ill., personal communication, July 1982.
36. Edson, J. R., McArthur, J. R., Branda, R. F., et al., "Successful Management of a Subdural Hematoma in a Hemophiliac With an Anti-Factor VIII Antibody," *Blood* 41:113-122, 1973.
37. Erskine, J. G., Burnett, A. K., Walker, I. D., et al., "Plasma Exchange in Non-Hemophiliac Patients With Inhibitors to Factor VIII," *Br. Med. J.* 283:760, 1981.
38. *Federal Register*, 46(116):31770, June 17, 1981.
39. Food and Drug Administration, Department of Health and Human Services, "Apheresis: Medical Therapy for the 80s," unpublished internal document (no date, Rockville, Md.) sent to the National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., May 26, 1982.
40. Foreman, R. M., National Kidney Foundation, Inc., New York, letter to the National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., no date.
41. Friedman, L., American Red Cross, Bethesda, Md., personal communication, December 1982.
42. Frost & Sullivan, Inc., "In-Vivo Hemodetoxification and Hemoprocessing Markets in the U.S.," unpublished, New York, June 1981.
43. Goldstein, M., National Institute of Neurological and Communication Disorders and Stroke, National Institutes of Health, Department of Health and Human Services, Bethesda, Md., personal communication, December 1982.
44. Grady, D., "Pumping Plasma," *Discover*, pp. 70-72, November 1980.
45. Gross, M. L. P., Sweny, P., and Legg, N. J., "Successful Plasmapheresis in the Miller-Fisher Syndrome," *Br. Med. J.* 282:1159, 1981.
46. Haemonetics Research Institute, "Guidelines for Therapeutic Apheresis," unpublished, Braintree, Mass., 1980.
47. Hamburger, M. I., Washington, D. C., personal communication, November 1982.
48. Hamburger, M. I., letter to Stephen HeySe, National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., no date.
49. Hamburger, M. I., State University of New York, Stony Brook, N. Y., personal communication, January 1983.
50. Harden, L. B., Bluck R. S., and Salcedo, J. R., "Simultaneous Hemodialysis and Exchange Transfusion in Hemolytic Uremic Syndrome," *Clin. Pediatr.* 19:640-642, 1980.
51. Health Care Financing Administration, Department of Health and Human Services, *Medicare Hospital Manual*, Coverage Issues Appendix, Sec. 35-50: Pheresis, Baltimore, Md., revision of Dec. 9, 1980.
52. Health Care Financing Administration, Department of Health and Human Services, *Medicare Hospital Manual*, Coverage Issues Appendix: Sec. 35-50: Pheresis, Baltimore, Md., Sept. 15, 1981.
53. Health Policy Alternatives, Inc., "Public and Private Payer Views on Reimbursement for Therapeutic Apheresis," unpublished, Washington, D. C., Jan. 20, 1982.
54. Heyse, S. P., National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., memorandum on "Coverage of Plasmapheresis," to Deputy Director, Office of Coverage Policy, Bureau of Program Policy, Health Care Financing Administration, Department of Health and Human Services, Baltimore, Md., Feb. 11, 1981.
55. HeySe, S. P., National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., memorandum on "Medicare Coverage Instruction on Pheresis," to Deputy Director, Office of Coverage Policy, Bu-

- reau of Program Policy, Health Care Financing Administration, Department of Health and Human Services, Baltimore, Md., Apr. 2, 1981.
56. Heyse, S. P., National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., memorandum on "Plasmapheresis—Your Memorandum of October 24, 1980," to Deputy Director, Office of Coverage Policy, Bureau of Program Policy, Health Care Financing Administration, Department of Health and Human Services, Baltimore, Md., Nov. 6, 1980.
 57. Heyse, S. P., National Institutes for Arthritis, Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Md., personal communication, December 1982.
 58. Heyse, S. P., National Institutes for Arthritis, Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Md., personal communication, July 1982.
 59. Heyse, S. P., Renault, P. R., and Perry, S., "National Center for Health Care Technology Assessment of Therapeutic Apheresis for Rheumatoid Arthritis, 1981," *J. Clin. Apheresis* 1:50-54, 1982.
 60. Hiatt, B., "Mutation Studies Go High-Tech.," *Research News* (University of Michigan), 33(6/7), June/July 1982.
 61. Hollis, T., Blue Cross-Blue Shield of Massachusetts, Boston, Mass., personal communication, February 1983.
 62. Hughes, R. A. C., Newsom-Davis, J., Armitage, P., et al., letter, *Br. Med. J.* 282:2056, 1981.
 63. Hughes, R. A. C., Newsom-Davis, J. M., Perkin, G. D., et al., "Controlled Trial of Prenisolone in Acute Polyneuropathy," *Lancet* 2:750-753, 1978.
 64. Irvine, A. T., and Tibbles, J., "Treatment of Fisher's Variant of Guillain-Barré Syndrome by Exchange Transfusion," *J. Can. Sci. Neurol.* 8:49-50, 1981.
 65. Isselbacher, K. J., *Harrison's Principles of Internal Medicine*, 9th ed. (New York: McGraw-Hill, 1980).
 66. Jones, J. V., Claugh, J. D., Klinenberg, J. R., et al., "The Role of Therapeutic Plasmapheresis in the Rheumatic Diseases," *J. Lab. Med.* 97:589-598, 1981.
 67. Jones, J. V., "Plasmapheresis in SLE," *Clinics in Rheum. Dis.* 8(1):243-260, 1982.
 68. Jones, J. V., et al., "Rape and Heresy," *Plasma Therapy* (Laux Co., Inc., Harvard, Mass.) 1(4):3-4, 1980.
 69. Jones, R. J., American Medical Association, Chicago, 111., letter to the National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., June 1, 1981.
 70. Kambic, H., and Nosé, Y., *Plasmapheresis: Historical Perspective, Therapeutic Applications, and New Frontiers* (Cleveland, Ohio: International Center for Artificial Organs and Transplantation, 1982).
 71. Kaplan, B. S., and Drummond, K. N., "The Hemolytic-Uremic Syndrome is a Syndrome," *N. Engl. J. Med.* 298:964-966, 1978.
 72. Kingsley, G. F., Haemonetics Corp., Braintree, Mass., letter to the National Center for Health Care Technology, Office of the Assistant Secretary for Health, Department of Health and Human Services, Rockville, Md., Sept. 14, 1981.
 73. LeCocq, J., "Therapeutic Apheresis Update: Report on the International Symposium on Plasmapheresis," unpublished, Montgomery Securities, San Francisco, June 15, 1982.
 74. Levy, J., Immunogenetics, Sherman Oaks, Calif., personal communication, January 1983.
 75. Levy, J., Immunogenetics, Sherman Oaks, Calif., letter to P. Renault, National Center for Health Care Technology, Office of the Assistant Secretary for Health, Department of Health and Human Services, Rockville, Md., July 14, 1980.
 76. Levy, R. L., Newkirk, R., and Ochoa, J., "Treating Chronic Relapsing Guillain-Barré Syndrome by Plasma Exchange," *Lancet* 2:259-260, 1979.
 77. Littlewood, R., and Bajada, S., "Successful Plasmapheresis in the Miller-Fisher Syndrome," *Br. Med. J.* 282:778, 1981.
 78. Maisey, D. N., and Olczak, S. A., "Successful Plasmapheresis in the Miller-Fisher Syndrome," *Br. Med. J.* 282:2055, 1981.
 79. Martini, J. A., Blue Cross/Blue Shield of Massachusetts, Boston, Mass., letter to S. P. Heyse, National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., Aug. 3, 1981.
 80. Marwick, C., "New Blood Washing Therapy: Catching on Big Despite Lack of Controlled Studies," *Med. World N.* 22:47-59, June 8, 1981.
 81. Mayr, U., Rumpl, E., Hackl, J. M., et al., "Treatment of Guillain-Barré Syndrome by Plasma Exchange, in *Plasma Exchange Therapy*, H. Borberg and P. Reuther (eds.) (Stuttgart: Georg Thieme Verlag, 1981).
 82. Mishler, J. M., Blood Resources Branch, Division of Blood Diseases and Resources, memorandum on "Apheresis" to Director, National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Md., Feb. 13, 1981.

83. Mishler, J. M., Blood Resources Branch, Division of Blood Diseases and Resources, memorandum on "Therapeutic Apheresis," to Director, National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Md., Mar. 2, 1981.
84. Misiani, R., Trevisan, F., Marchesi, D., et. al., "Plasmapheresis and Plasma Infusion in the Treatment of Hemolytic-Uremic Syndrome," *Hemostasis, Prostaglandins and Renal Disease* (New York: Raven Press, 1980).
85. Murt, H., "Therapeutic Plasmapheresis: A Medical Innovation in Search of Applications," unpublished, School of Public Health, University of Michigan, Ann Arbor, Mich., 1982.
86. National Center for Health Care Technology, "Apheresis in the Treatment of Rheumatoid Arthritis," *Assessment Report Series*, vol. 1, No. 6, Department of Health and Human Services, 1981.
87. National Institutes of Health—Progress Report, "Plasmapheresis Treatment of Acute Guillain-Barré," grant No. 1R01-NS 17053-01, 1981.
88. Nightingale, S. L., Acting Associate Commissioner for Health Affairs, Food and Drug Administration, memorandum on "Apheresis in the Treatment of Disease," to the National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., July 29, 1981.
89. Norris, F. H., Denys, E. H., and Mielke, C. H., "Plasmapheresis in Amyotrophic Lateral Sclerosis," in *Plasmapheresis and the Immunobiology of Myasthenia Gravis*, P. Dau (ed.) (Boston: Houghton Mifflin Professional Publishers, 1979).
90. Nosé, Y., and Malchesky, P. S., "Therapeutic Application of Plasmapheresis," *Plasma Q.* 1(4), 1979.
91. Office of Health Research, Statistics, and Technology, "Apheresis for Multiple Sclerosis," *Assessment Report Series*, vol. 2, No. 11, Department of Health and Human Services, Rockville, Md., 1982.
92. Office of Health Research, Statistics, and Technology, "Plasmapheresis and Plasma Exchange for Treatment of Thrombotic Thrombocytopenic Purpura," *Assessment Report Series*, vol. 2, No. 13, Department of Health and Human Services, Rockville, Md., 1982.
93. Office of Health Research, Statistics, and Technology, "Rheumatoid Vasculitis Therapeutic Apheresis," *Assessment Report Series*, vol. 2, No. 8, Department of Health and Human Services, Rockville, Md., 1982.
94. Office of Health Technology Assessment, "Apheresis for the Treatment of Goodpasture's Syndrome and Membranous Proliferative Glomerulonephritides," *Assessment Report Series*, vol. 3, Nos. 2 and 3, Department of Health and Human Services, Rockville, Md., 1983.
95. Office of Technology Assessment, U.S. Congress, *Assessing the Efficacy and Safety of Medical Technologies*, Washington, D. C., OTA-H-75, September 1978.
96. Office of Technology Assessment, U.S. Congress, *Development of Medical Technology: Opportunities for Assessment*, OTA-H-34, Washington, D. C., August 1976.
97. Office of Technology Assessment, U.S. Congress, "The Impacts of Randomized Clinical Trials on Health Policy and Medical Practice," preliminary draft, Washington, D. C., March 1983.
98. Office of Technology Assessment, U.S. Congress, *The Implications of Cost-Effectiveness Analysis of Medical Technology*, OTA-H-126, Washington, D. C., August 1980.
99. Office of Technology Assessment, U.S. Congress, *The Implications of Cost-Effectiveness Analysis of Medical Technology/Background Paper #1: Methodological Issues and Literature Review*, OTA-BP-H-5, Washington, D. C., September 1980.
100. Office of Technology Assessment, U.S. Congress, *The Implications of Cost-Effectiveness Analysis of Medical Technology/Background Paper #2: Case Studies of Medical Technologies*, 17 individually published case studies, Washington, D. C., 1980-1982.
101. Office of Technology Assessment, U.S. Congress, *The Implications of Cost-Effectiveness Analysis of Medical Technology/Background Paper #3: The Efficacy and Cost Effectiveness of Psychotherapy*, OTA-BP-H-6, Washington, D. C., October 1980.
102. Office of Technology Assessment, U.S. Congress, *Medical Technology and the Costs of the Medicare Program/Health Technology Case Study #22: The Effectiveness and Costs of Alcoholism Treatment*, OTA-HCS-22, Washington, D. C., March 1983.
103. Office of Technology Assessment, U.S. Congress, "The National Center for Health Care Technology and Medical Technology Assessment Policy," unpublished staff paper, Washington, D. C., March 17, 1981.
104. Office of Technology Assessment, U.S. Congress, *Strategies for Medical Technology Assessment*,

- OTA-H-181, Washington, D. C., September 1982.
105. Oldham, Robert K., National Cancer Institute, National Institutes of Health, Bethesda, Md., personal communication, December 1982.
 106. Parries, B., Duke, V. E., Simon, N. M., et al., "Adult Hemolytic-Uremic Syndrome Successfully Treated With Plasma Exchange," *Plasma Therapy* 3:57-61, 1981.
 107. Pease, E. A., "Report From NCHCT: Evaluation of Therapeutic Apheresis for Rheumatoid Arthritis," *J. A.M.A.* 246(10):1053, 1981.
 108. Phillips L. Scoville Associates, *Therapeutic PZasmapheresis: Review and Market Forecast*, Greenville, S. C., February 1981.
 109. Piller, G., Hocker, P., Ludwig, E., et al., "Plasmapheresis: Its Role in the Management of Inhibitor Patients," in *Workshop on Inhibitors of Factors VIII and IX, January 26th and 27th, 1976* (Vienna: Facultas-Verlas, 1977).
 110. Pineda, A. A., Brzica, S. M., and Taswell, H. F., "Continuous-, and Semicontinuous-Flow Blood Centrifuge Systems: Therapeutic Applications With Plasma-, Platelet-, Lympha-, and Eosinpheresis," *Transfusion* 17:407-416, 1977.
 111. Pintado, T., Taswell, H. F., and Bowie, E. J., "Treatment of Life-Threatening Hemorrhage Due to Acquired Factor VIII Inhibitor," *Blood* 46:535-541, 1975.
 112. Powell, L. C., "Intense Plasmapheresis in the Pregnant Rh-Sensitized Woman," *Am. J. Obstet. Gynecol.* 101:153, 1968.
 113. Rettig, R. A., "End-Stage Renal Disease and the 'Cost' of Medical Technology," in *Medical Technology: The Culprit Behind Health Care Costs*, proceedings of the 1977 Sun Valley Forum on National Health, S. H. Altman and R. Blendon (eds.), DHEW publication No. (PHS) 79-3216 (Washington, D. C.: U.S. Government Printing Office, August 1977).
 114. Révész, T., Mátyus, J., Goldschmidt, B., et al., "Control of Life-Threatening Bleeding by Combined Plasmapheresis and Immunosuppressive Treatment in a Hemophiliac With Inhibitors," *Arch. Dis. Child.* 55:641-643, 1980.
 115. Riegelman, R. K., "Plasmapheresis in Guillain-Barré Syndrome," prepared for the Office of Technology Assessment, U.S. Congress, September 1982.
 116. Robbins, F., "Assessing the Consequences of Biomedical Research," in *Medical Technology: The Culprit Behind Health Care Costs*, proceedings of the 1977 Sun Valley Forum on National Health, S. H. Altman and R. Blendon (eds.), DHEW publication No. (PHS) 79-3216 (Washington, D. C.: U.S. Government Printing Office, August 1977).
 117. L. F. Rothschild, Unterberg, Towbin, "Therapeutic Apheresis," unpublished, New York, Sept. 11, 1981.
 118. Rothwell, R. S., Davis, P., Gordon, P. A., et al., "A Controlled Study of Plasma Exchange in the Treatment of Severe Rheumatoid Arthritis," *Arth. & Rheumat.* 23:785-790, 1980.
 119. Rumpl, E., et al., "Treatment of Guillain-Barré Syndrome by Plasma Exchange," *J. Neurol.* 225: 207-217, 1981.
 120. Samtleben, W., Blumenstein, M., Liebl, L., et al., "Membrane Plasma Separates for Treatment of Immunologically Medicated Disease," *Trans. Am. Soc. of Artif. Int. Org.* 26:12-16, 1980.
 121. Sandier, G. S., American Red Cross, Washington, D. C., personal communication, December 1982.
 122. Saxe, L., and Fine, M., *Social Experiments: Methods for Design and Evaluation* (Beverly Hills, Calif.: Sage Publications, Inc., 1981).
 123. Schooneman, F., Janet, C., Streiff, F., et al., "Plasma Exchange in Guillain-Barré Syndrome: Ten Cases," *Plasma Ther.* 2:117-121, 1981.
 124. Schweitzer, S., and Foxman, B. H., UCLA School of Public Health, "The Effect of Third Party Reimbursement on Expenditures for Medical Care," prepared at the request of the National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., Sept. 15, 1981.
 125. Scoville, P., Greenville, S. C., personal communication, December 1982.
 126. Seger, R., Joller, P., and Baerlocher, K., "Hemolytic-Uremic Syndrome Associated With Neuraminidase-Producing Micro-Organisms: Treatment by Plasma Exchange," *Helv. Paediatr. Act.* 35:359-367, 1980.
 127. Simon, T., "Overview of the Efficacy of Therapeutic Apheresis," presented at Plasma Forum V, Washington, D. C., June 1982.
 128. Simon, T., United Blood Services, Albuquerque, N. M., letter to S. P. Heyse, National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., Sept. 11, 1981.
 129. Slocombe, G. W., Newland, A. C., and Colvin, M. P., "The Role of Intensive Plasma Exchange in the Prevention and Management of Haemorrhage in Patients With Inhibitors to Factor VIII," *Br. J. Haematol.* 47:577-585, 1981.
 130. Sutton, D. M. C., Cardella, C. J., Udall, P. R.,

- et al., "Complications of Intensive Plasma Exchange," *Plasma Ther.* 2:19-23, 1981.
131. Sweny, P., Winning, A., Gross, M., et al., "Plasmapheresis in the Haemolytic-Uraemic Syndrome in Children," *Br. Med. J.* 282:2137, 1981.
 132. Taft, E. G., and Baldwin, S. T., "Plasma Exchange Transfusion," *Semin. Thromb. Hemostas.* 7:15-21, 1981.
 133. Thomas, L., *Lives of a Cell* (New York: Viking Press, 1974).
 134. Valbonesi, M., Mosconi, L., Garelli, S., et al., "Successful Treatment by Plasma Exchange in Guillain-Barré Syndrome With Immune Complexes," *Vox Sang.* 38:181-184, 1980.
 135. Viatel, P., Chenais, F., Dechelette, D., et al., "Adult Hemolytic Uremic Syndrome Successfully Treated With Plasma Exchange," *Kidney Int.* 15:453, 1979.
 136. Vibert, G. J., Parker-Hannifin Corp., Irvine, Calif., personal communication, August 1982.
 137. Waldenstrom, J. G., "Plasmapheresis—Bloodletting Revived and Refined," *Acta Med. Scand.*, 208:1-4, 1980.
 138. Wallace, D. J., Goldfinger, D., and Gatti, R., "Plasmapheresis and Lymphoplasmapheresis in the Management of Rheumatoid Arthritis," *Arth. & Rheumat.* 22:703-710, 1979.
 139. Wallace, D. J., Goldfinger, D., Lowe, C., et al., "A Double-Blind, Controlled Study of Lymphoplasmapheresis Versus Sham Apheresis in Rheumatoid Arthritis," *N. Engl. J. Med.* 306(23):1406-1410, 1982.
 140. Wallace, D. J., Goldfinger, D., Thompson-Breton, R., et al., "Advances in the Use of Therapeutic Pheresis for the Management of Rheumatic Diseases," *Sem. Arth. & Rheumat.* 10:81-91, 1980.
 141. Warner, K. E., "A 'Desperation-Reaction' Model of Medical Diffusion," *Health Serv. Res.* 10:369-383, 1975.
 142. Warner, W. L. (cd.), *Plasma Forum IV: February 11-13, 1981*, American Blood Resources Association, no city, no date.
 143. Wensley, R. T., Stevens, R. F., Burn, A. M., et al., "Plasma Exchange and Human Factor VIII Concentrate in Managing Hemophilia A With Factor VIII Inhibitors," *Br. Med. J.* 281:1388-1389, 1980.
 144. Wenz, B., and Barland, P., "Therapeutic Intensive Plasmapheresis," *Sem. Hematol.* 18(2):147-162, 1981.
 145. Wohlreich, J. J., Travenol Laboratories, Inc., letter to the National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., Sept. 14, 1981.
 146. Wortman, P. M., and Murt, H. (in collaboration with Bruce Friedman), "Plasmapheresis for Hemolytic-Uremic Syndrome and Factor VIII Inhibitor," prepared for the Office of Technology Assessment, U.S. Congress, October 1982.
 147. Wortman, P. M., and Saxe, L., "The Assessment of Medical Technology: Methodological Considerations," prepared for the Office of Technology Assessment, U.S. Congress, Appendix C in *Strategies for Medical Technology Assessment*, OTA-H-181, Washington, D. C., September 1981.
 148. Wyngaarden, J. B., and Smith, L. H. (eds.), *Cecil Textbook of Medicine*, 16th ed. (Philadelphia, Pa.: W. B. Saunders Co., 1982).
 149. Young, D. A., Deputy Director, Office of Coverage Policy, Bureau of Program Policy, Health Care Financing Administration, Department of Health and Human Services, Baltimore, Md., memorandum on "Coverage of Apheresis" to Associate Director for Medical and Scientific Evaluation, National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., May 11, 1981.
 150. Young, D. A., Deputy Director, Office of Coverage Policy, Bureau of Program Policy, Health Care Financing Administration, Department of Health and Human Services, Baltimore, Md., memorandum on "Coverage of Plasmapheresis," to Director, National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., Jan. 13, 1981.
 151. Young, D. A., Deputy Director, Office of Coverage Policy, Bureau of Program Policy, Health Care Financing Administration, Baltimore, Md., memorandum on "Medicare Coverage Instructions on Pheresis," to Director, National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., Dec. 12, 1980.
 152. Young, D. A., Deputy Director, Office of Coverage Policy, Bureau of Program Policy, Health Care Financing Administration, Department of Health and Human Services, Baltimore, Md., memorandum on "NCHCT Regarding Plasmapheresis in the Treatment of Rheumatoid Arthritis," to Associate Director for Medical and Scientific Evaluation, National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., June 15, 1981.
 153. Young, D. A., Deputy Director, Office of Coverage Policy, Bureau of Program Policy, Health

Care Financing Administration, Department of Health and Human Services, Baltimore, Md., memorandum on "Medicare Coverage Instructions on Pheresis," to Director, National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., Mar. 11, 1981.

154. Young, D. A., Office of Coverage Policy, Bureau

of Program Policy, Health Care Financing Administration, Department of Health and Human Services, Baltimore, Md., memorandum on "Plasmapheresis—Memorandum of August 25, 1980" to Associate Director for Medical and Scientific Evaluation, National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., Oct. 24, 1980.